- Home
- ABTS vs PPBT Comparison
ABTS vs PPBT Comparison
Compare ABTS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | PPBT |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 45.3M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ABTS | PPBT |
|---|---|---|
| Price | $1.64 | $3.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 18.5K | 13.5K |
| Earning Date | 04-30-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.35 | $0.41 |
| 52 Week High | $10.86 | $5.18 |
Technical Indicators
Market Signals| Indicator | ABTS | PPBT |
|---|---|---|
| Relative Strength Index (RSI) | 26.13 | 63.89 |
| Support Level | N/A | $0.57 |
| Resistance Level | $3.00 | $5.18 |
| Average True Range (ATR) | 0.27 | 0.37 |
| MACD | -0.07 | -0.13 |
| Stochastic Oscillator | 3.48 | 68.57 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.